Table 3.

Clinical Variables Associated With Anticoagulation Prescription in Multivariable Logistic Regression Analysis: Full Cohort (N = 472)^∗

Covariate	Adjusted Odds Ratio (95% CI)
Age 65–74 yrs (vs. <65 yrs)	2.04 (1.01–4.25)
Age ≥75 yrs (vs. <65 yrs)	2.65 (1.30–5.52)
Gender (female vs. male)	0.74 (0.44–1.22)
Hypertension	2.50 (1.50–4.22)
Heart failure	2.38 (0.95–6.29)
Prior atrial fibrillation	3.02 (1.86–4.96)
Diabetes	0.84 (0.47–1.48)
Prior stroke	1.67 (1.03–2.82)
Vascular disease	0.82 (0.44–1.51)
Renal disease	0.24 (0.07–0.77)
Liver disease	0.89 (0.03–12.39)
Prior major bleeding	0.09 (0.03–0.23)
Labile INR	1.09 (0.13–12.22)
VTE	2.83 (1.04–8.24)
Chemotherapy, current use (vs. no use)	0.55 (0.32–0.93)
Chemotherapy, noncurrent, prior 3 months (vs. no use)	0.50 (0.24–1.05)
Perioperative atrial fibrillation	0.38 (0.22–0.65)
NSAID	0.31 (0.17–0.56)
Ibrutinib†	—
Platelet count <50,000/μl	0.10 (0.01–0.38)
Karnofsky score	1.00 (0.97–1.03)
LVEF	0.99 (0.94–1.04)
Brain metastases	0.12 (0.01–0.93)

CI = confidence interval; other abbreviations as in Table 1.

^∗All variables listed in the table were included in the multivariable model; all variables were categorized as binary (yes or no), with the exception of age, categorized as <65 years, 65 to 74 years, or ≥75 years; Karnofsky score, categorized as 0 to 100; and LVEF, categorized as 0 to 100. All cancer subtypes indicated in Tables 1 and 2 were also included in the model to control for confounding.

^†None of the patients treated with ibrutinib were prescribed anticoagulation.